Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

<p>DEG Table for R vs NR (mRNAseq)</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Gregory L. Beatty (15087193) (author)
Altres autors:	Devora Delman (15129986) (author), Jiayi Yu (16743347) (author), Mingen Liu (16743350) (author), Joey H. Li (15129989) (author), Liti Zhang (16743353) (author), Jae W. Lee (16743356) (author), Renee B. Chang (15129983) (author), Nathan Bahary (16743359) (author), Eugene P. Kennedy (16743362) (author), Andrea Wang-Gillam (15049923) (author), Gabriela R. Rossi (16743365) (author), Ignacio Garrido-Laguna (15131889) (author)
Publicat:	2025
Matèries:	Cancer Therapeutic Research and Development Chemotherapy Gastrointestinal Cancers Pancreatic cancer Translational Research
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
per: Gregory L. Beatty (15087193)
Publicat: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
per: Jiachun Su (16990970)
Publicat: (2025)

Image 9_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 8_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 6_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 7_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 4_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 5_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Image 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
per: Xiangjun Wang (2522917)
Publicat: (2025)

Table 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
per: Xiangjun Wang (2522917)
Publicat: (2025)

Table 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
per: Xiangjun Wang (2522917)
Publicat: (2025)

Table 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
per: Xiangjun Wang (2522917)
Publicat: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
per: Erika Y. Faraoni (14844897)
Publicat: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
per: Erika Y. Faraoni (14844897)
Publicat: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
per: Erika Y. Faraoni (14844897)
Publicat: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
per: Yan Zhou (15053225)
Publicat: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S4 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S5 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S6 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S7 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Movie S8 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
per: Fang Wei (15057172)
Publicat: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
per: Arun Kanakkanthara (14937731)
Publicat: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
per: Elizabeth R. Tucker (15053624)
Publicat: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
per: Dwight H. Owen (15034782)
Publicat: (2025)

Supplementary Table 1 from Comprehensive DNA Methylation Analysis Indicates That Pancreatic Intraepithelial Neoplasia Lesions Are Acinar-Derived and Epigenetically Primed for Carcinogenesis
per: Emily K.W. Lo (15618846)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_at0eul1nsfl608ceh0jdaunf02